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Transcriptional perturbation 
of protein arginine 
methyltransferase‑5 exhibits 
MTAP‑selective oncosuppression
Sara Busacca1, Qi Zhang2, Annabel Sharkey1, Alan G. Dawson1,6, David A. Moore3,4, 
David A. Waller5, Apostolos Nakas6, Carolyn Jones7, Kelvin Cain7, Jin‑li Luo1, 
Adriana Salcedo8,9,10, Iris Chiara Salaroglio11, Chiara Riganti11, John Le Quesne1,7, Tom John12, 
Paul C. Boutros8, Shu‑Dong Zhang13 & Dean A. Fennell1* 
We hypothesized that small molecule transcriptional perturbation could be harnessed to target 
a cellular dependency involving protein arginine methyltransferase 5 (PRMT5) in the context 
of methylthioadenosine phosphorylase (MTAP) deletion, seen frequently in malignant pleural 
mesothelioma (MPM). Here we show, that MTAP deletion is negatively prognostic in MPM. In vitro, 
the off‑patent antibiotic Quinacrine efficiently suppressed PRMT5 transcription, causing chromatin 
remodelling with reduced global histone H4 symmetrical demethylation. Quinacrine phenocopied 
PRMT5 RNA interference and small molecule PRMT5 inhibition, reducing clonogenicity in an MTAP‑
dependent manner. This activity required a functional PRMT5 methyltransferase as MTAP negative 
cells were rescued by exogenous wild type PRMT5, but not a PRMT5E444Q methyltransferase‑dead 
mutant. We identified c‑jun as an essential PRMT5 transcription factor and a probable target for 
Quinacrine. Our results therefore suggest that small molecule‑based transcriptional perturbation 
of PRMT5 can leverage a mutation‑selective vulnerability, that is therapeutically tractable, and has 
relevance to 9p21 deleted cancers including MPM.
Deletion of chromosome 9p21 encompasses the tumour suppressors CDKN2A and methylthioadenosine phos-
phorylase (MTAP)1,2, and is a frequent somatic event in several  cancers1,2. MTAP is a critical enzyme in the 
methionine salvage pathway that metabolizes the substrate methylthioadenosine (MTA), leading to regeneration 
of methionine and  adenosine3. Deletion of MTAP has been reported to confer a vulnerability to inhibition of the 
epigenetic regulator protein arginine methyltransferase 5 (PRMT5), which symmetrically methylates arginine 
on histone H4, leading to chromatin  remodelling2,4,5.
Malignant pleural mesothelioma (MPM) is an incurable cancer caused by asbestos that lacks effective tar-
geted therapies, and harbours high frequency deletion of  9p216,7. Here we report a negative prognostic impact 
of MTAP on survival of patients with MPM, and demonstrate potential to selectively target somatic deletion of 
MTAP using a small-molecule based strategy, involving PRMT5 transcriptional suppression.
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Results
MTAP is negatively prognostic in MPM. MTAP copy number loss was assessed in 79 mesotheliomas 
acquired at radical surgery involving extended pleurectomy decortication (EPD) (Supplementary Table I). Copy 
number loss of 9p21.3 encompassing CDKN2A/MTAP was observed in 47% (37 samples) of patients and 42% 
had MTAP deletion (33 samples); co-deletion of MTAP and CDKN2A was frequent (95%). MTAP heterozy-
gous or homozygous deletion was associated with shorter median overall survival (OS) compared to wild-type 
MTAP, 12.5 (95%CI 6.8–18.2) versus 17.6 (95%CI 6.5–28.7) months respectively, p = 0.042, HR 0.609 (95%CI 
0.376–0.987), (Fig. 1A). In an independent validation cohort of 100 samples (Supplementary Table I), 63% of 
patients harboured MTAP deletion (63 samples); co-deletion of MTAP and CDKN2A was similarly at high fre-
quency (83%). MTAP deletion was associated with shorter overall survival (OS) compared to wild-type MTAP, 
8.7 (95%CI 4.6–12.8) versus 22.7 months (95% CI 11.4–33.9) months respectively, p = 0.021, HR 0.599 (95%CI 
0.386–0.930) (Fig. 1B).
To explore MTAP as a covariate, we performed a univariate analysis showing a statistically significant effect 
between overall survival with: age (p = 0.02); iMig stage (p = 0.009) and MTAP status (p = 0.008). These vari-
ables were taken forward into a Cox multivariate analysis showing that iMig stage (HR 1.36 (95%CI 1.11–1.68), 
p = 0.003) and MTAP status (HR 1.41 (95%CI 1.03–1.93), p = 0.032) retained statistical significance whilst age 
(HR 1.32 (95%CI 0.97–1.79), p = 0.08) did not.
PRMT5 silencing mediates growth arrest in MTAP negative mesothelioma. To determine 
whether MTAP negative MPM cells were dependent on PRMT5, we silenced PRMT5 expression by RNA 
interference in both MTAP wild-type and negative MPM cell lines (Fig. 1C). Reduced clonogenic growth was 
selective for MTAP negative cell lines, with concurrent reduction in symmetrical di-methylation of Histone H4 
arginine 3 (H4R3me2S). Silencing of the PRMT5 interactor WDR77 phenocopied PRMT5 silencing in MTAP 
negative cells, leading to a reduced clonogenic activity and a reduced H4R3me2S (Fig. 1D). This effect was not 
phenocopied by siRNA targeting the PRMT5 interactor RIO1 kinase (Supplementary Fig. 1A).
To investigate the kinetics of growth arrest, we conducted real time analysis following PRMT5 RNAi which 
showed a growth arrest after 120 h (Fig. 2A). Neither apoptosis nor cell cycle perturbation were observed by flow 
cytometry after PRMT5 silencing (Supplementary Fig. 1B).
To determine whether or not PRMT5 silencing-induced chromatin remodelling would upregulate tumour 
suppressor pathways, we conducted gene expression, examining canonical pathways linked to upregulated genes. 
Overexpression of tumour suppressors, such as EIF3F, FOXP4, ZBTB4, GANAB, TMEM141 was observed. Gene 
set enrichment analysis revealed a significant enrichment of the EZH2 target gene (Fig. 2B,C, Supplementary 
Table 2).
In common with PRMT5 siRNA, the small molecule EPZ015666 reduced clonogenic growth (Supplemen-
tary Fig. 1C). Neither apoptosis nor cell cycle perturbation were observed by flow cytometry after inhibition by 
EPZ015666 (Supplementary Fig. 1D).
Quinacrine hydrochloride is a PRMT5 perturbagen. To fully harness the potential for MTAP selective 
activity via PRMT5 inhibition, we utilised the connectivity  map8 to identify novel transcriptional suppressors 
of PRMT5 (Supplementary Table 3, Fig. 3A). Among the top 5 predicted molecules, Quinacrine Hydrochloride 
led to significant suppression of both PRMT5 mRNA levels (Fig. 3B) and protein with consequent reduction of 
H4R3me2S and growth arrest in MTAP negative but not MTAP positive cells (Fig. 3C). Quinacrine Hydrochlo-
ride directly inhibited PRMT5 promoter activity as confirmed by luciferase reporter assay (Fig. 3D), but did not 
have any direct effect on PRMT5 enzymatic activity (Fig. 3E).
Neither apoptosis nor cell cycle perturbation were observed after treatment with Quinacrine by flow cytom-
etry, in common with both PRMT RNA interference or small molecule inhibitor (Supplementary Fig. 2A). We 
used a functional genetic approach to establish the extent to which the phenotypic effects of Quinacrine in MTAP 
negative cells were reliant upon PRMT5. Overexpression of wild-type PRMT5 rescued cells from treatment with 
Quinacrine, however this was not observed with transfection of the methyltransferase dead mutant  PRMT5E444Q 
compared to empty vector control. This is consistent with modulation of endogenous PRMT5 transcription as an 
essential mechanism underpinning the effect of Quinacrine in MTAP negative context (Fig. 3F).
Quinacrine transcriptionally regulates PRMT5 via c‑JUN. To further explore the possible mecha-
nism of PRMT5 transcriptional perturbation by Quinacrine, we used RNA interference to screen for puta-
tive transcription factors (TFs) implicated by  PROMO9. These TFs included CEBP1, c-JUN and NF-YA were 
predicted to bind to the PRMT5 promoter. RNAi mediated silencing of c-JUN, but not of CEBP1 or NF-YA, 
resulted in a significant reduction of PRMT5 mRNA levels in MTAP negative cells and this was comparable to 
that achieved with Quinacrine (Fig. 4A). c-JUN silencing led to reduced clonogenic growth with concurrent 
downregulation of both PRMT5 and H4R3me2S in MTAP negative cells (Fig. 4B), but no apoptosis or cell cycle 
perturbation (Supplementary Fig. 2B). Quinacrine suppressed c-JUN mRNA suggesting that it targets PRMT5 
transcription indirectly via this transcription factor (Fig. 4C). The effects of c-JUN silencing were MTAP-selec-
tive, as MTAP positive cells failed to reduce PRMT5 mRNA (Fig. 4D), without evidence of impaired clonogenic 
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Figure 1.  MTAP is negatively prognostic in MPM (A) Kaplan–Meier survival curve for OS of MTAP positive 
and MTAP negative patients (n = 79). (B) Kaplan–Meier survival curve for OS of MTAP positive and MTAP 
negative patients from validation cohort (n = 100). (C) MTAP negative cells (NCI-H2052, NCI-H2591) 
and MTAP positive cells (MPP89) were transfected with siNT or siPRMT5 20 nM (Q: Qiagen sequence, 
D: Dharmacon sequence). Cell proliferation was measured by clonogenic assay 5–7 days after transfection. 
Data were normalized to siNT controls (NCI-H2591: Q p = 0.0001 D p = 0.0001; NCI-H2052: Q p = 0.0001 
D p = 0.0001; NCI-H2452: Q p = 0.0001 D p = 0.0001; MPP89: Q p = n.s. D p = n.s.). The levels of PRMT5 
expression and H4 arginine 3 symmetrical di-methylation (H4R3me2S) were measured by western blot 72 h 
after transfection. These gels have been cropped and full length gels are presented in Supplementary Fig. 3A–C. 
(D) Cells were transfected with siNT or siWDR77 20 nM. Cell proliferation was measured by clonogenic 
assay 5–7 days after transfection. Data were normalized to siNT controls (NCI-H2591: p = 0.0001; NCI-
H2052: p = 0.0001; NCI-H2452: p = n.s; MPP89: p = n.s.). The levels of PRMT5 expression and H4 arginine 3 
symmetrical di-methylation (H4R3me2S) were measured by western blot 72 h after transfection. These gels have 
been cropped and full length gels are presented in Supplementary Fig. 3D–F.
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Figure 2.  PRMT5 silencing mediates growth arrest in MTAP negative mesothelioma. (A) NCI-H2591 
cells were transfected with siNT or siPRMT5 (Q: qiagen sequence, D: Dharmacon sequence) 20 nM. Cell 
proliferation was measured for 168 h with the excelligence real-time cell analyser. Data were normalized 
to siNT controls (Q p = 0.0015 D p = 0.0019). (B) Venn diagram showing upregulated and downregulated 
genes comparing the PRMT5 siRNAs versus siNT. (C) Heatmaps and representative GSEA plots showing a 
significantly enriched up regulated signatures (siPRMT5 vs. siNT).
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Discussion
Copy number loss of MTAP is one of the most frequent events in MPM. Our data confirmed a marked negative 
prognostic effect, which warrants novel targeted therapy. It should be noted that given the co-deletion of MTAP 
with CDKN2A, which has been also shown to be negatively prognostic, it was not possible to deconvolute the 
impact of MTAP in isolation from our data involving chromosome 9p21.3 deleted cel lines. PRMT5 plays a key 
role in the regulation of several pathways including DNA damage response, apoptosis, inhibition of tumour 
suppressors, and activation of survival  pathways10 and has been reported to be a dependency in MTAP negative 
 cells11, which we have verified in MPM. We confirmed global epigenetic modification associated with reduced 
H4R3me2S and re-expression of tumour suppressors, such as EIF3F, FOXP4, ZBTB4, GANAB, TMEM141, in 
association with loss of clonogenicity.
SAM competitive PRMT5 inhibitors, such as EPZ015666 and GSK3326595, have shown limitations in reca-
pitulating the vulnerability of MTAP negative cells in response to PRMT5  inhibition10. To address this limitation, 
we used the connectivity map  approach8 to screen for small molecules with PRMT5 downregulating activity and 
identified the off-patent small molecule Quinacrine, which was primarily used as an antimalarial drug as well as 
an intrapleural sclerosing treatment for malignant pleural effusions with an excellent safety  profile12. Quinacrine-
mediated growth arrest was PRMT5 dependent as confirmed by a methyltransferase dead PRMT5 mutant.
Apoptosis was not observed as a mechanism of reduced clonogenicity; the phenotype was cytostatic, but not 
restricted to any phase of the cell cycle. Recent studies suggest that small molecule PRMT5 inhibition, either directly 
or indirectly through inhibition of cyclin dependent kinases 4 and 6, alters RNA splicing, leading to an MDM4 
dependent activation of p53/p2113,14. Whether this axis is exploited by Quinacrine requires further exploration.
Quinacrine has been reported to regulate c-jun phosphorylation at positions 349 to 340 and 266 to  25715. We 
showed that c-jun is essential in driving PRMT5 expression and mediating Quinacrine-induced apoptosis. This 
study therefore implicates c-jun or SAPK pathway regulation as a mechanism underlying PRMT5 transcriptional 
repression by Quinacrine.
Based on early pharmacokinetic studies conducted with Quinacrine in the 1940′s, plasma concentration was 
measured as 225 nM at a dose of 100 mg, 3 times a day. However, hepatic and leucocyte distributions are high, 
with high plasma binding. This agent can however be safely instilled into the pleural cavity at a much higher 
dose of 5 mM, at which dose it acts as a sclerosant. This implies that lower micromole doses are achievable and 
could be locally administered, achieving localised exposure to mesothelioma at concentrations capable of sup-
pressing PRMT5 expression.
Our results provide a proof of concept to support the use of small molecule transcriptional perturbation to 
leverage a somatic-mutation based vulnerability, suggesting a repurposing potential that warrants further study.
Material and methods
Patient samples. Seventy-nine patient MPM samples were obtained at the time of extended pleurectomy 
decortication (EPD) under ethical approval. This study was approved by the London-Fulham Research Ethics 
Committee (reference 14/LO/1527), The Northampton Research Ethics Committee (reference 14/EM/1159) and 
University Hospitals Leicester NHS Trust Research and Innovation Department (reference UHL 11,363). Patient 
clinico-pathological characteristics are outlined in Supplementary Table I. Overall survival was calculate from 
the date of surgery. A separate cohort of 100  patients16 was used for validation and clinico-pathological char-
acteristics are described in Supplementary Table I. Informed consent to provide research samples was obtained 
from all patients. All methods were carried out in accordance with local guidelines and regulations.
Oncoscan analysis. DNA was extracted with the GeneRead DNA FFPE kit (Qiagen, Manchester, UK). 
80 ng of gDNA were analysed using the OncoScan FFPE Assay Kit (Affymetrix, Wooburn Green High Wycombe, 
UK), which utilizes molecular inversion probe (MIPs)  technology17. The BioDiscovery Nexus Express 10.0 for 
OncoScan software was then used to define copy number alterations and loss of heterozygosity as previously 
 described18.
Reagents and antibodies. Quinacrine was purchased from Sigma (Gillingham, UK). The antibodies 
against MEP50, PRMT5 and c-JUN were obtained from Cell Signaling (Hitchin, UK), MTAP antibody was 
purchased from Santacruz (Wembley, UK), H4R3me2S and β-tubulin were obtained from Abcam (Cambridge, 
UK). Goat anti-rabbit HRP and donkey anti-mouse HRP secondary antibodies were from Cell Signaling 
(Hitchin, UK).
Cell lines. MPM cell lines: NCI-H2052, were purchased from ATCC (Middlesex, UK). MPP89 and NCI-
H2591 were kindly provided by Dr. P.W. Szlosarek, Institute of Cancer at Barts, London, UK. Cell lines were 
grown in RPMI Medium 1640, 1% L-Glutamine and 10% FBS (Gibco, Loughborough, UK).
Clonogenic assays. 5000 cells per well were seeded in 12 well plates and left untreated or treated with 
Quinacrine (500 nM, 1 µM, 2 µM). Cells were fixed between days five and seven (once enough colonies had 
formed in the control) on ice in methanol for 10 min. Cells were then stained with crystal violet (Sigma, Gill-
ingham, UK) for 20 min. Colonies were dissolved in 30% acetic acid to allow  quantification19. Each treatment 
condition was measured in triplicate.
siRNA transfections. The non-silencing control (NT), siPRMT5, siWDR77, sic-JUN, siCEBPB, siNF-
YA were obtained from Qiagen (Manchester, UK). siRNA transfections (20  nM) were performed using the 
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RNAiMAX transfection reagent (Invitrogen, Paisley, UK) according to manufacturer’s instructions. Validation 
of siPRMT5 and siWDR77 was carried out with a second sequence from Dharmacon (Little Chalfont, UK).
Real time proliferation assay. The xCELLigence RTCA DP instrument (Acea Bioscience, San Diego, 
CA) was used as described in the manufacturer´s instruction manual. Cells (5,000 cells/ well) were seeded in 
E16-Plates. The cell indices were measured every 15 min for 120 h. Each treatment condition was measured in 
triplicate.
Connectivity mapping. A PRMT5-centred gene signature was created from co-expression analyses 
of 9 independent Gene Expression Omnibus (GEO) datasets GSE37745, GSE50081, GSE28571, GSE77803, 
GSE43580, GSE19804, GSE18842, GSE10245, and GSE19188. Within each dataset, PRMT5 was used as the seed 
gene, with which the gene expression correlation coefficients for other genes (probes) were calculated. All genes 
were then ranked based on the magnitude and statistical significance of their correlations with the seed, follow-
ing the ranking method described  in18. The genes’ ranks were then combined across these datasets to obtain an 
overall rank for each gene to determine its inclusion to the PRMT5 gene signature for subsequent connectivity 
mapping analysis. A gene signature progression  approach19 determined that an 8-gene signature was the optimal 
length including PRMT5 and its 7 strongest co-expression correlates PSMB5, HNRNPC, APEX1, HNRNPC, 
IPO4, TOX4, and TUBB. This 8-gene signature was used as an input to query a collection of 83,939 reference 
drug gene expression  profiles20 covering 1353 FDA approved drugs (http:// www. lincs cloud. org). This connectiv-
ity mapping analysis was conducted in the framework of  sscMap21,22. In our analysis all the individual reference 
profiles with the same drug formed a reference set. A set score was then calculated between the gene signature 
and each reference set, and the associated p-value was estimated by generating a large number of random gene 
signatures of the same length. Any signature-drug connections with a p-value no greater than a pre-set threshold 
(1/1353 = 7.4e−4) were declared as statistically significant. Additionally, gene signature perturbation  analysis23 
was performed to obtain the robustness (perturbation stability) of the significant signature-drug connections. 
Only the significant drugs that had 100% perturbation stability were selected for further consideration. Finally, 
significant drugs were ranked by the absolute value of their connection z-score to the PRMT5 gene signature.
PRMT5 enzymatic activity. PRMT5 chemoluminescent assay was purchased from AMS Biotechnology 
(Europe) Ltd (Abingdon, UK). Quinacrine or EPZ015666 was added to the plate pre-coated with histone H4 
peptide substrate. PRMT5 enzymatic activity was measured after reaction with the antibody against methylated 
arginine3 residue of Histone H4, the secondary HRP-labeled antibody, S-adenosylmethionine, methyltrans-
ferase assay buffer, and purified PRMT5 enzyme, according to the manufacturer instructions.
Protein extraction and immunoblotting. Seventy-two hours after treatment cells were lysed in RIPA 
buffer containing protease inhibitors (Roche, Burgess Hill, UK). Lysates were clarified by centrifugation at 4 °C at 
13,000 rpm for 10 min. 40 µg of total cell lysates were loaded on SDS-PAGE gels. Signal detection was performed 
with ECL-plus chemiluminescent system (GE Healthcare, Little Chalfont, UK).
Real time quantitative RT‑PCR. Total RNA was extracted using Trizol (Invitrogen, Paisley, UK) accord-
ing to manufacturer’s instructions. Reverse transcription was performed with High Capacity RNA-to-cDNA Kit 
(Applied Biosystem, Paisley, UK). Real-Time PCR was carried out using Power SYBR Green PCR Master Mix 
(Applied Biosystem, Paisley, UK) after 72 h of silencing or treatment with Quinacrine. QuantiTect primer assays 
(Qiagen, Manchester, UK) were used for PRMT5, c-JUN and Actin.
Figure 3.  Identification of Quinacrine Hydrochloride as a PRMT5 perturbagen. (A) Connectivity mapping 
analysis showing quinacrine as transcriptional suppressor of PRMT5. (B) PRMT5 mRNA expression was 
evaluated by qRT-PCR on RNA extracted from cells treated with Quinacrine 1 µM for 72 h. Data were 
normalized to untreated control (NCI-H2052 p = 0.0308; NCI-H2591: p = 0.0063; MPP89 p = 0.005). (C) Cells 
were left untreated or treated with Quinacrine 0.5 µM and 1 µM for 72 h. Cell proliferation was measured by 
clonogenic assay 5–7 days after treatment. Data were normalized to untreated controls (NCI-H2591: 0.5 µM 
p = n.s. 1 µM p = 0.0001; NCI-H2052: .5 µM p = n.s. 1 µM p = 0.0017; MPP89: 0.5 µM p = n.s. 1 µM p = n.s.). 
The levels of PRMT5 expression and H4 arginine 3 symmetrical di-methylation (H4R3me2S) were measured 
by western blot 72 h after transfection. These gels have been cropped and full length gels are presented in 
Supplementary Fig. 3G–I. (D) The PRMT5 promoter activity was measured by a luciferase reporter assay in 
NCI-H2591 cells transfected with pGL2 basic (EV) or pGL2-PRMT5 and then treated with Quinacrine 1 µM 
for 72 h. Data were normalized to pGL2 basic (pGL2 basic vs. pGL2-PRMT5 NT p = 0.0162; pGL2 basic vs. 
pGL2-PRMT5 1 µM p = n.s.; pGL2-PRMT5 NT vs. pGL2-PRMT5 1 µM p = 0.0335). (E) Cells were left untreated 
or treated with Quinacrine or EPZ015666 10 nM, 100 nM, 1 µM and 10 µM. PRMT5 enzymatic activity was 
measured after 2 h. (F) NCI-H2591 cells were transfected with GFP empty vector, PRMT5 WT and PRMT5 
E444Q and left untreated or treated with Quinacrine 0.5 µM and 1 µM for 72 h. Cell proliferation was measured 
by clonogenic assay 5–7 days after treatment. Data were normalized to untreated controls (Empty vector: NT vs. 
0.5 µM p = 0.0004, NT vs1 µM p < 0.0001; PRMT5 E444Q: NT vs. 1 µM p = 0.0026; Empty vector 1 vs. PRMT5 
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Reporter assay. Cells were transfected with pGL2 basic or pGL2-PRMT5 and Renilla by using the Xtreme 
gene transfection reagent (Sigma, Gillingam, UK) according to the manufacturer’s instructions. After 24 h cells 
were treated with Quinacrine and 72 h after transfection cells were lysed and stored at -80 °C for at least 24 h. 
The luciferase activity was then measured by a Dual-Luciferase reporter assay system (Promega, Southampton, 
UK). Luciferase activity was normalized to Renilla  activity19.
Overexpression of PRMT5. NCI-H2591 cells were transfected with 2 µg of PRMT5 (WT or mutant) or 
empty vector, using the Xtreme gene transfection reagent (Sigma, Gillingham, UK) according to the manufac-
turer’s instructions. Selection of stable clones was performed with G418 500 μg/ml (Sigma, Gillingham, UK).
Site directed mutagenesis. The Quick change II site directed mutagenesis kit (Agilent, Cheadle, UK) was 
used according to manufacturer instructions to introduce a mutation in PRMT5 (E444Q).
Statistical analysis. Dose–response curves were fitted using non-linear regression (GraphPad Prism ver-
sion 6.0, GraphPad Software, LaJolla, CA, USA). The significance of the data has been assessed with t-test (two 
tails), or One-way ANOVA. All data are representative of the mean and standard deviation for at least three 
independent experiments. Kaplan–Meier curves for overall survival were used to assess survival estimates of the 
cohorts. Univariate analyses comparing the clinical variables with overall survival were performed using the log 
rank test and all statistically significant clinical variables were taken forward into a multivariate Cox regression 
model. The data was analysed using SPSS Version 25 (Armonk, NY, IBM Corp). All p-values less than or equal 
to 0.05 were considered significant.
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sic-JUN p = 0.0006; siNF-YA p = 0.0033. NCI-H2052: siCEBP1 p = 0.0001; sic-JUN p = 0.0009; siNF-YA 
p = 0.0001). (B) Cell proliferation was measured by clonogenic assay 5–7 days after treatment. Data were 
normalized to siNT (NCI-H2591: siCEBP1 p = n.s.; sic-JUN p = 0.0073; siNF-YA p = n.s. NCI-H2052: siCEBP1 
p = n.s.; sic-JUN p = 0.0001; siNF-YA p = 0.0001). The levels of PRMT5 and c-JUN expression and H4 arginine 3 
symmetrical di-methylation (H4R3me2S) were measured by western blot. These gels have been cropped and full 
length gels are presented in Supplementary Fig. 3J–K. (C) C-JUN mRNA expression was evaluated by qRT-PCR 
on RNA extracted from cells treated for 72 h with Quinacrine 1 µM. Data were normalized to untreated controls 
(NCI-H2591 p = 0.0001. NCI-H2052 p = 0.0276). (D) PRMT5 and cJUN mRNA expression was evaluated by 
qRT-PCR on RNA extracted from MPP89 cells transfected with siNT, sic-JUN 20 nM, for 72 h. Data were 
normalized to siNT (PRMT5 p = n.s. c-JUN p = 0.0205). (E) Cell proliferation was measured by clonogenic assay 
5–7 days after treatment. Data were normalized to siNT (sic-JUN p = n.s). The levels of PRMT5 and c-JUN 
expression and H4 arginine 3 symmetrical di-methylation (H4R3me2S) were measured by western blot. This gel 
has been cropped and the full length gel is presented in Supplementary Fig. 3L. (F) C-JUN mRNA expression 
was evaluated by qRT-PCR on RNA extracted from cells treated for 72 h with quinacrine 1 µM. Data were 
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Supplementary table I. Patient characteristics 
 
 UK cohort (n=79) AUS cohort (n=100) 
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Gene 
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2029 ENSA X X X X   X     X                   X X 
 




X X X 
          
X 













        
X X 
          
X 








23193 GANAB X     X           X                 X   
 
S glucosidase, alpha; neutral AB 
22927 HABP4 X     X               X   X     X       
 
S hyaluronan binding protein 4 
85014 TMEM14
1 X 
    X                     X           
 
S transmembrane protein 141 
4 
 
11054 OGFR X             X                 X X     
 
S opioid growth factor receptor 
84717 HDGFRP
2 X 
                
X X 





related protein 2 
84263 HSDL2 
X 




    
X 








                        
X 
            
 
S 





                        
X 










OSBPL5 X                                       
 
S oxysterol binding protein-like 5 
84331 FAM195
A X 





195, member A 
90317 ZNF616 X                                       
 
S zinc finger protein 616 
84687 PPP1R9B   
X X 
    
X 
  
X X X 









EVI5L   
X 
  
X X X X 
    
X X 






2801 GOLGA2   X   X   X                     X       
 
S golgin A2 
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zinc finger and 
BTB domain 
containing 4 
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X X X 

































family, member 9B 
(with GRAM 
domain) 
23299 BICD2   
X 










4720 NDUFS2   
X 
      
X 
            
X X 
    
X X 











10811 NOXA1   X         X                           
 
S NADPH oxidase activator 1 
5886 RAD23A   X                                     
 
S RAD23 homolog A (S. cerevisiae) 
59 ACTA2   
X 
                                    
 
S 
actin, alpha 2, 
smooth muscle, 
aorta 




          
X 




binding protein 4 
(formin binding 
protein 21) 
29924 EPN1       X   X                             
 
S epsin 1 
57804 POLD4       X       X   X     X         X     
 
S polymerase (DNA-directed), delta 4 
11520
9 
OMA1       
X 
                    
X 







2802 GOLGA3       X                       X         
 
S golgin A3 
37492
0 
C19orf68       
X 




open reading frame 
68 
5433 POLR2D       
X 








FOXP4       X                                 
 
S forkhead box P4 
51754 TMEM8B       X                                 
 
S transmembrane protein 8B 
11093 ADAMT
S13 
      
X 







type 1 motif, 13 
29123 ANKRD1
1 
          X   X         X               
 
S ankyrin repeat domain 11 
22864 R3HDM2           X   X                         
 
S R3H domain containing 2 
2036 EPB41L1           
X 
        
X 





band 4.1-like 1 
84265 POLR3G
L 
          
X 




III (DNA directed) 
polypeptide G 
(32kD)-like 
7461 CLIP2           
X 






23373 CRTC1           
X 






25875 LETMD1               X   X                     
 
S LETM1 domain containing 1 
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X X 
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X 







9790 BMS1                     
X 






8665 EIF3F                       
X 











                      
X 
                
 
S 
zinc finger with 
KRAB and SCAN 
domains 1 
1632 ECI1                         X   X       X   
 
S enoyl-CoA delta isomerase 1 
166 AES                           X             
 
S amino-terminal enhancer of split 
23265 EXOC7                             X X       X 
 
S exocyst complex component 7 
55624 POMGN
T1 
                              
X X 








3913 LAMB2                                   X     
 
S laminin, beta 2 (laminin S) 
8733 GPAA1                                   
X 






1 homolog (yeast) 
20306
9 





R3H domain and 
coiled-coil 
containing 1 
23351 KHNYN                                       X 
 
S KH and NYN domain containing 
23229 ARHGEF
9 












3, member A 
25870 SUMF2                                         
 
S sulfatase modifying factor 2 
593 BCKDH
A 











ZNF664                                         
 
S zinc finger protein 664 
79090 TRAPPC
6A 

















                                        
 
S uncharacterized LOC642852 






7637 ZNF84                                         
 
S zinc finger protein 84 
11367
5 
SDSL                                         
 
S serine dehydratase-like 




open reading frame 
93 
23408 SIRT5                                         
 
S sirtuin 5 
55420
3 







90321 ZNF766                                         
 
S zinc finger protein 766 
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Supplementary Table 3 Connectivity map analysis 
Drug Replicate p value Z score 
    
BRD-K71103788__duloxetine hcl 48 1.85E-10 -6.2659907 
BRD-K75641298__METOCLOPRAMIDE 
HYDROCHLORIDE 
29 2.77E-09 -5.8298123 
BRD-K36862742__hydro-flumethiazide 141 3.04E-08 -5.4165957 
BRD-K99964838__S1014 66 6.16E-08 -5.2888016 
BRD-A45889380__QUINACRINE 
HYDROCHLORIDE 
206 8.03E-08 -5.240004 
BRD-K91699951__benzonatate 234 1.39E-07 -5.1383754 
BRD-K71879491__ATRA 205 2.17E-07 -5.0531872 
BRD-A51820102__econazole 36 2.22E-07 -5.0489293 
BRD-K37270826__mifepristone 125 2.62E-07 -5.0175175 
BRD-K70487031__cis-(Z)-
FLUPENTHIXOL 
27 3.03E-07 -4.9893544 
BRD-K63675182__triflupromazine 179 5.12E-07 -4.8868451 
BRD-K89375097__pirenzepine 36 6.96E-07 -4.826062 
BRD-K19706299__MRE-269 99 7.54E-07 -4.8102311 
BRD-K32164935__TOLAZAMIDE 353 1.17E-06 -4.7219067 
BRD-K28936863__ketotifen 85 1.18E-06 -4.7204909 
BRD-A23723433__paclitaxel 48 1.22E-06 -4.7138292 
BRD-K39621635__artemether 34 1.25E-06 -4.7081455 
BRD-K81418486__SAHA__trt_poscon 12 1.36E-06 -4.6910799 
BRD-K92093830__doxorubicin 159 1.58E-06 -4.6599437 
BRD-A49160188__donepezil 73 1.74E-06 -4.6404777 
BRD-K70487031__flupentixol 37 2.14E-06 -4.5971052 
BRD-K10916986__S1527 67 2.20E-06 -4.5915996 
BRD-K92778217__mefenamic-acid 160 2.39E-06 -4.5741376 
BRD-K13514097__S1120 58 3.79E-06 -4.4764562 
BRD-K45995181__Auranofin 3 3.84E-06 -4.474083 
BRD-K66175015__S1011 59 4.68E-06 -4.4316279 
BRD-K53737926__amitryptiline 137 4.95E-06 -4.4194573 
BRD-K52075040__cerulenin 210 5.16E-06 -4.4103748 
BRD-K20075662__betazole 143 5.27E-06 -4.4059091 
BRD-K33106058__cytarabine 48 5.52E-06 -4.395691 
BRD-K91290917__Amodiaquin 
dihydrochloride dihydrate 
57 5.65E-06 -4.3905396 
BRD-K81418486__vorinostat 1303 6.50E-06 -4.360225 
BRD-K93754473__tamoxifen 843 6.59E-06 -4.3571007 
BRD-K25433859__maprotiline 37 9.22E-06 -4.2829289 
BRD-K39339537__epirizole 217 1.16E-05 -4.2316941 
BRD-A45889380__Quinacrine 
dihydrochloride dihydrate 
10 1.58E-05 -4.1619013 
BRD-K81528515__HY-10159 66 1.60E-05 -4.1585908 
9 
 
BRD-K17016787__estriol 355 1.78E-05 -4.1344654 
BRD-K21680192__mitoxantrone 334 1.91E-05 -4.1181513 
BRD-K41260949__Sodium Valproate 45 2.33E-05 -4.0721889 
BRD-K39987650__BISACODYL 93 2.54E-05 -4.0520213 
BRD-K89997465__CHLORPROMAZINE 86 2.68E-05 -4.0390003 
BRD-
K81418486__VORINOSTAT__trt_poscon 
2575 3.07E-05 -4.0072094 
BRD-K63750851__mycophenolic-acid 31 3.78E-05 -3.9582377 
BRD-K47869605__podofilox 72 3.85E-05 -3.9538222 
BRD-K61250553__Loperamide.HCl 23 3.91E-05 -3.9501318 
BRD-K20168442__vecuronium 49 4.36E-05 -3.9234926 
BRD-K61250553__imodium 45 4.38E-05 -3.9224636 
BRD-A29734509__norpace 44 5.30E-05 -3.8764725 
BRD-K28143534__Cyproheptadine 
hydrochloride 
10 1.07E-04 -3.7019795 
BRD-K86434416__deprenalin 88 1.31E-04 -3.6498136 
 
SUPPLEMENTARY METHODS 
Clonogenic assays  
5000 cells per well were seeded in 12 well plates and left untreated or treated with 
EPZ015666 (1 µM, 5 µM, 10 µM). The PRMT5 inhibitor EPZ015666 was obtained from 
Selleckchem (Ely, UK). 
Five days after treatment, cells were fixed on ice in methanol for 20 minutes. Cells 
were then stained with crystal violet (Sigma, Gillingham, UK) for 10 minutes. Colonies 
were dissolved in 30% acetic acid to allow quantification. Each treatment condition 
was measured in triplicate. 
 
siRNA transfections  
The non-silencing control (NT) and siRIOK, were obtained from and Qiagen 
(Manchester, UK). siRNA transfections (20 nM) were performed using the RNAiMAX 




Flow Cytometry  
Samples were analysed on a BD FACS Calibur flow cytometer machine, using Cell 
Quest Pro software (Becton Dickinson, Oxford, UK). Cells were fixed after 16, 32, 72 
and 120 hours of treatment with quinacrine, EPZ015666 or after silencing of PRMT5 
and stained with propidium iodide (Sigma).  
 
Gene expression  
NCI-H2591 and NCI-H2052 cells were transfected with non-silencing control (NT), 
siPRMT5 Qiagen and siPRMT5 Dharmacon. RNA was extracted 120h after 
transfection with the RNeasy Mini Kit (Qiagen, Manchester, UK) and 100 ng of RNA 
were hybridised on the SurePrint G3 Human Gene Expression v3 8x60k array (Agilent, 
Cheadle, UK).  
 
Gene expression dataset was analysed using Limma in R/Bioconductor software 
package.  Comparisons were performed siQ vs siNT, siD vs siNT.  Gene lists were 
then filtered by fold change ≥2, unadjusted p value ≤ 0.05. Webgestalt 
(http://www.webgestalt.org/) was used to perform Gene Ontology, KEGG pathway, 
Pathway Common, Wiki Pathway. GSEA Molecular Signatures Database 
(http://software.broadinstitute.org/gsea/msigdb/index.jsp) was used to investigate 85 





SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. A) Cells were transfected with siNT or siRIOK1 20 nM. Cell 
proliferation was measured by clonogenic assay. Data were normalized to siNT 
controls (NCI-H2591: p= n.s.; NCI-H2052: p=0.0001; NCI-H2452: p=n.s; MPP89: p= 
n.s.). The levels of PRMT5 expression and H4 arginine 3 symmetrical di-methylation 
(H4R3me2S) were measured by western blot 72 hours after transfection. These gels 
have been cropped and the full length gels are presented in Supplementary Figure 3 
M-O. B) Flow cytometry plot showing cells transfected with siNT or siPRMT5 for 120 
hours. C) Cells were left untreated or treated with EPZ015666 1µM, 5 µM and 10µM. 
Cell proliferation was measured by clonogenic assay 5-7 days after treatment. Data 
were normalized to untreated controls (NCI-H2591: 1 µM p=0.0176; 5 µM p=0.0001; 
10 µM p=0.0001; NCI-H2052: 1 µM p=n.s.; 5 µM p= n.s. 10 µM p=0.0033; MPP89: 1 
µM p=n.s.; 5 µM p= n.s. 10 µM p= n.s.). D) Flow cytometry plot showing cells left 
untreated or treated with EPZ015666 5 µM and 10µM for 72 hours. 
 
Supplementary Figure 2. Flow cytometry plot showing cells left untreated or treated 
with quinacrine 1 µM for 120 hours. B) Flow cytometry plot showing cells transfected 
with siNT, sic-JUN 20 nM, for 120 hours.  
Supplementary Figure 3. Uncropped images of full length gels used throughout the 
manuscript. A-C: Full length gels of cropped gels in Figure 1C (A: NCI-H2591; B: NCI-
H2052; C: MPP89); D-F: Full length gels of cropped gels in Figure 1D (D: NCI-H2591; 
E: NCI-2052; F: MPP89); G-I: Full length gels of cropped gels in Figure 3C (G: NCI-
H2591; H: NCI-H2052; I: MPP89); J-K: Full length gels of cropped gels in Figure 4B 
(J: NCI-H2591; K: NCI-H2052); L: Full length gel of cropped gel in Figure 4E; M-O: 
12 
 
Full length gels of cropped gels in Supplementary Figure 1A (M: NCI-H2591; N: NCI-
H2052; O: MPP89). 



























Supplementary Figure 3. 
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